Read by QxMD icon Read

European Journal of Cancer

Elske C Gootjes, Lotte Bakkerus, Albert J Ten Tije, Petronella O Witteveen, Tineke E Buffart, John A Bridgewater, John N Primrose, Cornelis Verhoef, Henk M W Verheul
Local treatment of metastases by surgical resection or other ablative therapies is technically feasible in an increasing number of patients with multi-organ metastatic cancer. This results in a growing debate on whether patients with extensive disease, that is traditionally deemed unresectable, may benefit from local treatment of metastases when added to standard palliative systemic therapy. For selected patients with oligometastatic colorectal cancer, local treatment of metastases has become the standard of care based on retrospective reports showing long-term survival rates...
September 19, 2018: European Journal of Cancer
Fabien Calvo, Giovanni Apolone, Michael Baumann, Carlos Caldas, Julio E Celis, Franceso de Lorenzo, Ingemar Ernberg, Ulrik Ringborg, John Rowell, Josep Tabernero, Emile Voest, Alexander Eggermont
Translational cancer research covers the whole cancer research continuum from basic to preclinical to early clinical, late clinical and outcomes research. Basic-preclinical research is the "engine" for early clinical research bridging the early translational research gap. Cancer Core Europe has been created to construct a sustainable, high level, shared research infrastructure platform with research collaborations and taskforces (data sharing, clinical trials, genomics, immunotherapy, imaging, legal & ethical problems, and education & training) having representatives from all seven member centres, in a controlled expansion model...
September 18, 2018: European Journal of Cancer
Mario Campone, Seock-Ah Im, Hiroji Iwata, Mark Clemons, Yoshinori Ito, Ahmad Awada, Stephen Chia, Agnieszka Jagiełło-Gruszfeld, Barbara Pistilli, Ling-Ming Tseng, Sara Hurvitz, Norikazu Masuda, Javier Cortés, Michele De Laurentiis, Carlos L Arteaga, Zefei Jiang, Walter Jonat, Sylvie Le Mouhaër, Banu Sankaran, Laurence Bourdeau, Mona El-Hashimy, Dalila Sellami, José Baselga
BACKGROUND: Buparlisib, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, plus fulvestrant in the BELLE-2 study significantly improved progression-free survival (PFS) in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. PATIENTS AND METHODS: In this phase III study, patients were randomised 1:1 to buparlisib (100 mg/day; continuously in 28-day cycles) or placebo, plus fulvestrant (500 mg on cycle 1 day 15, and day 1 of subsequent cycles)...
September 18, 2018: European Journal of Cancer
Dorothy M Gujral, Susan J Cleator, Sanjeev Bhattacharyya
Identification and quantification of the cardiac adverse effects of new cancer therapeutics is important when comparing treatment arms in clinical trials. Heart failure and left ventricular dysfunction are some of the most common adverse cardiac effects of a range of cancer treatments, including anthracyclines, trastuzumab and other targeted agents. Using the example of trastuzumab-induced cardiac dysfunction, we evaluated phase III clinical trials performed over the past decade to establish the methods used to identify heart failure and impairment of left ventricular function...
September 17, 2018: European Journal of Cancer
Corinne Balleyguier, Morgane Cousin, Ariane Dunant, Marie Attard, Suzette Delaloge, Julia Arfi-Rouche
We evaluated the impact of patient-assisted compression (PAC) on image quality, dose, workflow and patient experience of mammography. Patients aged 40-90 years coming for bilateral mammography were included prospectively in the study. After positioning each breast, the technologist performed the compression and exposure of the first breast, initiated the compression of the other until 3 daN and then let the patient complete the compression using a remote control device. Image quality, compression force, breast thickness, average glandular dose and pain value for each breast were assessed for PAC and technologist compression (TC)...
September 14, 2018: European Journal of Cancer
Ji-Yeon Kim, Seock-Ah Im, Kyung Hae Jung, Jungsil Ro, Joohyuk Sohn, Jee Hyun Kim, Yeon Hee Park, Tae-Yong Kim, Sung-Bae Kim, Keun Seok Lee, Gun Min Kim, Se Hyun Kim, Seonwoo Kim, Jin Seok Ahn, Kyung-Hun Lee, Jin-Hee Ahn, In Hae Park, Young-Hyuck Im
BACKGROUND: We investigated the efficacy and safety of fulvestrant plus goserelin (F + G) versus anastrozole plus goserelin (A + G) in comparison with goserelin (G) alone in premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), tamoxifen-pretreated metastatic breast cancer (MBC). PATIENTS AND METHODS: In this multicentre, open-label, randomised phase II study, premenopausal women aged ≥18 years with HR+, HER2-, tamoxifen-pretreated MBC were randomly assigned (1:1:1) to F + G, A + G or G alone...
September 14, 2018: European Journal of Cancer
Bastien Cabarrou, Patrick Sfumato, Loïc Mourey, Eve Leconte, Laurent Balardy, Alejandra Martinez, Jean-Pierre Delord, Jean-Marie Boher, Etienne Brain, Thomas Filleron
INTRODUCTION: Cancer in the elderly is a major public issue. However, older patients have long been debarred from clinical trials. There is a high unmet medical need for specific trials addressing oncology strategies adapted to older patients' conditions. While randomised phase III trials remain the gold standard, they usually require large numbers of patients. In this perspective, late single-arm phase II trials assessing treatment feasibility might prove a good alternative. However, it is essential to take into account the heterogeneity in an ageing population characterised by frailty...
September 14, 2018: European Journal of Cancer
Clara Prud'homme, Fréderic Deschamps, Adrien Allorant, Christophe Massard, Antoine Hollebecque, Steve Yevich, Maud Ngo-Camus, Guillaume Gravel, Claudio Nicotra, Stefan Michiels, Jean-Yves Scoazec, Ludovic Lacroix, Eric Solary, Jean-Charles Soria, Thierry De Baere, Lambros Tselikas
PURPOSE: To evaluate efficacy, complications and preprocedural risk factors for percutaneous image-guided core needle biopsy of malignant tumours for genomic tumour analysis. MATERIALS AND METHODS: Procedural data for core biopsies performed at a single centre for the MOSCATO-01 clinical trial were prospectively recorded between December 2011 and March 2016. Data assessed included patient demographics, tumour characteristics, procedural outcomes and complications...
September 14, 2018: European Journal of Cancer
Tsuyoshi Hamada, Li Liu, Jonathan A Nowak, Kosuke Mima, Yin Cao, Kimmie Ng, Tyler S Twombly, Mingyang Song, Seungyoun Jung, Ruoxu Dou, Yohei Masugi, Keisuke Kosumi, Yan Shi, Annacarolina da Silva, Mancang Gu, Wanwan Li, NaNa Keum, Kana Wu, Katsuhiko Nosho, Kentaro Inamura, Jeffrey A Meyerhardt, Daniel Nevo, Molin Wang, Marios Giannakis, Andrew T Chan, Edward L Giovannucci, Charles S Fuchs, Reiko Nishihara, Xuehong Zhang, Shuji Ogino
BACKGROUND: High-level plasma 25-hydroxyvitamin D [25(OH)D] has been associated with lower colorectal cancer incidence and mortality. Considering evidence indicating immunomodulatory effects of vitamin D, we hypothesised that survival benefits from high systemic vitamin D level might be stronger for colorectal carcinoma with lower immune response to tumour. METHODS: Using 869 colon and rectal cancer cases within the Nurses' Health Study and Health Professionals Follow-up Study, we assessed the prognostic association of postdiagnosis 25(OH)D score [derived from diet and lifestyle variables to predict plasma 25(OH)D level] in strata of levels of histopathologic lymphocytic reaction...
September 12, 2018: European Journal of Cancer
Olivier Mir, Analia Azaro, Jaime Merchan, Rashmi Chugh, Jonathan Trent, Jordi Rodon, Ute Ohnmacht, J T Diener, Claire Smith, Eunice Yuen, Gerard Joseph Oakley, Axel Le Cesne, Jean-Charles Soria, Karim A Benhadji, Christophe Massard
BACKGROUND: LY3039478 is an orally bioavailable selective Notch inhibitor. This phase 1a/b trial evaluated the safety, pharmacokinetics and antitumour activity of LY3039478 in patients with soft tissue sarcoma (STS) and gastrointestinal stromal tumour (GIST). METHODS: This multipart, phase 1 trial enrolled patients with refractory advanced/metastatic STS and GIST, measurable disease, Eastern Cooperative Oncology Group ≤1 and baseline tumour tissue. Eligible patients received LY3039478 50mg/75 mg three times per week, for 28-day cycle until disease progression...
September 12, 2018: European Journal of Cancer
Susan Feyerabend, Fred Saad, Tracy Li, Tetsuro Ito, Joris Diels, Suzy Van Sanden, Peter De Porre, Julie Roiz, Seye Abogunrin, Maria Koufopoulou, Karim Fizazi
AIM: Androgen deprivation therapy (ADT) has long been the gold standard for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Clinical trials have demonstrated significant survival benefits when docetaxel (DOC) or abiraterone acetate (AA) and prednisone (P) are added to ADT, necessitating comparison of these combination treatments. METHODS: A systematic review of randomised controlled trials (RCTs) of AA-/ADT-/DOC-containing treatment regimens in newly diagnosed patients with high-risk and/or high-volume mHSPC identified three RCTs (LATITUDE, CHAARTED and GETUG-AFU 15)...
September 12, 2018: European Journal of Cancer
Christian Simon, Carmela Caballero, Vincent Gregoire, Dietmar Thurnher, Petri Koivunen, Philippe Ceruse, Giuseppe Spriano, Piero Nicolai, Lisa Licitra, Jean-Pascal Machiels, Marc Hamoir, Guy Andry, Hisham Mehanna, Keith D Hunter, Andreas Dietz, C René Leemans
Quality improvement of care for patients with head and neck cancer remains a constant objective for the multidisciplinary team of physicians managing these patients. The purpose of quality assurance (QA) for head and neck surgical oncology and surgical trials however differs. While QA for the general head and neck patient aims to improve global outcome through structural changes of health-care systems, QA for surgical trials pursues the goal to help providing meaningful results from a clinical trial through the definition of structure, process and outcome measures within the trial...
September 11, 2018: European Journal of Cancer
E Paillaud, P Soubeyran, P Caillet, T Cudennec, E Brain, C Terret, F Etchepare, L Mourey, T Aparicio, F Pamoukdjian, R A Audisio, S Rostoft, A Hurria, C Bellera, S Mathoulin-Pélissier
BACKGROUND: To define a core set of geriatric data to be methodically collected in clinical cancer trials of older adults, enabling comparison across trials. PATIENTS AND METHODS: Following a consensus approach, a panel of 14 geriatricians from oncology clinics identified seven domains of importance in geriatric assessment. Based on the international recommendations, geriatricians selected the mostly commonly used tools/items for geriatric assessment by domain (January-October 2015)...
September 10, 2018: European Journal of Cancer
Johan M van Rooijen, Si-Qi Qiu, Hetty Timmer-Bosscha, Bert van der Vegt, James E Boers, Carolien P Schröder, Elisabeth G E de Vries
INTRODUCTION: Although targeting human epidermal growth factor receptor 2 (HER2) is a meaningful treatment in HER2-positive breast cancer, ultimately resistance develops. Androgen receptor (AR) expression and immune cell infiltration are thought to be involved in trastuzumab response and may, therefore, be of interest as additional targets for therapy in HER2-positive breast cancer. AIM: To improve insights into the presence among AR expression, immune cell infiltration and HER2, we analysed HER2-positive breast tumours...
September 9, 2018: European Journal of Cancer
Theresa Steeb, Anja Wessely, Thomas Ruzicka, Markus V Heppt, Carola Berking
BACKGROUND: BRAF and MEK inhibitors have demonstrated significant survival benefits for patients with cutaneous melanoma. However, their use for uveal melanoma (UM) is less established. The aim of this systematic review was to summarise the current evidence on the efficacy and safety of MEK inhibitors in metastatic UM. METHODS: We performed a systematic literature search in MEDLINE, Embase and the Cochrane Library CENTRAL from 1946 through 17 April 2018. Abstracts of oncologic conferences, trial registers and reference lists were handsearched for relevant publications...
September 8, 2018: European Journal of Cancer
Chor-Kuan Lim, Yu-Feng Wei, Mao-Song Tsai, Kuan-Yu Chen, Jin-Yuan Shih, Chong-Jen Yu
INTRODUCTION: Afatinib is commonly used as the first-line treatment for EGFR-mutated lung adenocarcinoma. However, dose adjustments are frequently required. This study aimed to investigate the treatment effectiveness of afatinib administered at different doses to patients with EGFR-mutated lung adenocarcinoma. METHODS: Treatment-naïve patients with advanced EGFR-mutated lung adenocarcinoma who received afatinib therapy between May 2014 and September 2016 were enrolled retrospectively...
September 7, 2018: European Journal of Cancer
Elie El Rassy, Ziad Bakouny, Fares Yared, Dania Nehme Chelala, Fadi El Karak, Marwan Ghosn
No abstract text is available yet for this article.
September 6, 2018: European Journal of Cancer
Yasemin Hirst, Sandro Stoffel, Gianluca Baio, Lesley McGregor, Christian von Wagner
BACKGROUND: The initial roll-out of the English Bowel (Colorectal) Cancer Screening programme, during 2006 and 2009, found uptake to be low (54%) and socially graded. The current analysis used data from 2010 to 2015 to test whether uptake is increasing and becoming less socially graded over time. METHODS: Postcode-derived area-level uptake of 4.4 million first-time invitees, stratified by gender and the year of the first invitation (2010-2015), was generated using the National Bowel Cancer Screening System...
September 6, 2018: European Journal of Cancer
Fausto Petrelli, Raffaele Ardito, Karen Borgonovo, Veronica Lonati, Mary Cabiddu, Mara Ghilardi, Sandro Barni
INTRODUCTION: Programmed cell death-1 or ligand 1 (PD-(L)1) inhibitors are associated with immune-related adverse events. Conversely, little is known about the incidence of haematological toxicities across published trials. We have performed a systematic review and meta-analysis to evaluate the incidence of immunotherapy-related anaemia, neutropenia and thrombocytopenia among different tumour types, trials phases and anti-PD-(L)1 agents. MATERIAL AND METHODS: A PubMed, Embase and Cochrane library search on 23rd December 2017 and a review of references from relevant articles were done...
September 6, 2018: European Journal of Cancer
M J F Smith, H G Smith, K Joshi, M Gore, D C Strauss, A J Hayes, J Larkin
INTRODUCTION: The outcomes of patients with metastatic melanoma have significantly improved with the introduction of effective systemic therapies (ESTs). The role of surgery in the context of ESTs for stage IV melanoma is evolving. We sought to characterise the changing patterns of surgery and oncological outcomes in patients with stage IV melanoma treated before and after the establishment of ESTs. METHODS: Patients undergoing surgical resection of stage IV melanoma were identified from our institutional database from 2003 to 2015...
September 6, 2018: European Journal of Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"